Dynamic Ultrasound Molecular-targeted Imaging of Senescence in Evaluation of Lapatinib Resistance in HER2-positive Breast Cancer

Overview

Journal Cancer Med

Specialty Oncology

Date 2023 Oct 4

PMID 37792675

Authors

Xiaoyu Chen

Ying Li

Zhiwei Zhou

Yanqiu Zhang

Luchen Chang

Xiujun Gao

Qing Li

Hao Luo

Kenneth D Westover

Jialin Zhu

Xi Wei

Affiliations

Soon will be listed here.

Abstract

Background: Prolonged treatment of HER2+ breast cancer with lapatinib (LAP) causes cellular senescence and acquired drug resistance, which often associating with poor prognosis for patients. We aim to explore the correlation between cellular senescence and LAP resistance in HER2+ breast cancer, screen for molecular marker of reversible senescence, and construct targeted nanobubbles for ultrasound molecular imaging to dynamically evaluate LAP resistance.

Methods And Results: In this study, we established a new cellular model of reversible cellular senescence using LAP and HER2+ breast cancer cells and found that reversible senescence contributed to LAP resistance in HER2+ breast cancer. Then, we identified ecto-5'-nucleotidase (NT5E) as a marker of reversible senescence in HER2+ breast cancer. Based on this, we constructed NT5E-targeted nanobubbles (NT5E-FITC-NBs) as a new molecular imaging modality which could both target reversible senescent cells and be used for ultrasound imaging. NT5E-FITC-NBs showed excellent physical and imaging characteristics. As an ultrasound contrast agent, NT5E-FITC-NBs could accurately identify reversible senescent cells both in vitro and in vivo.

Conclusions: Our data demonstrate that cellular senescence-based ultrasound-targeted imaging can identify reversible senescence and evaluate LAP resistance effectively in HER2+ breast cancer cells, which has the potential to improve cancer treatment outcomes by altering therapeutic strategies ahead of aggressive recurrences.

Citing Articles

Cellular senescence and SASP in tumor progression and therapeutic opportunities.

Dong Z, Luo Y, Yuan Z, Tian Y, Jin T, Xu F Mol Cancer. 2024; 23(1):181.

PMID: 39217404 PMC: 11365203. DOI: 10.1186/s12943-024-02096-7.

Dynamic ultrasound molecular-targeted imaging of senescence in evaluation of lapatinib resistance in HER2-positive breast cancer.

Chen X, Li Y, Zhou Z, Zhang Y, Chang L, Gao X Cancer Med. 2023; 12(19):19904-19920.

PMID: 37792675 PMC: 10587953. DOI: 10.1002/cam4.6607.

References

Chen X, Li Y, Zhou Z, Zhang Y, Chang L, Gao X . Dynamic ultrasound molecular-targeted imaging of senescence in evaluation of lapatinib resistance in HER2-positive breast cancer. Cancer Med. 2023; 12(19):19904-19920. PMC: 10587953. DOI: 10.1002/cam4.6607. View

Gavas S, Quazi S, Karpinski T . Nanoparticles for Cancer Therapy: Current Progress and Challenges. Nanoscale Res Lett. 2021; 16(1):173. PMC: 8645667. DOI: 10.1186/s11671-021-03628-6. View

Fass L . Imaging and cancer: a review. Mol Oncol. 2009; 2(2):115-52. PMC: 5527766. DOI: 10.1016/j.molonc.2008.04.001. View

Ortiz-Montero P, Londono-Vallejo A, Vernot J . Senescence-associated IL-6 and IL-8 cytokines induce a self- and cross-reinforced senescence/inflammatory milieu strengthening tumorigenic capabilities in the MCF-7 breast cancer cell line. Cell Commun Signal. 2017; 15(1):17. PMC: 5418812. DOI: 10.1186/s12964-017-0172-3. View

Neo S, Yang Y, Record J, Ma R, Chen X, Chen Z . CD73 immune checkpoint defines regulatory NK cells within the tumor microenvironment. J Clin Invest. 2019; 130(3):1185-1198. PMC: 7269592. DOI: 10.1172/JCI128895. View

McDermott M, Conlon N, Browne B, Szabo A, Synnott N, OBrien N . HER2-Targeted Tyrosine Kinase Inhibitors Cause Therapy-Induced-Senescence in Breast Cancer Cells. Cancers (Basel). 2019; 11(2). PMC: 6406301. DOI: 10.3390/cancers11020197. View

Palazzo A, Hernandez-Vargas H, Goehrig D, Medard J, Vindrieux D, Flaman J . Transformed cells after senescence give rise to more severe tumor phenotypes than transformed non-senescent cells. Cancer Lett. 2022; 546:215850. DOI: 10.1016/j.canlet.2022.215850. View

Turcotte M, Allard D, Mittal D, Bareche Y, Buisseret L, Jose V . CD73 Promotes Resistance to HER2/ErbB2 Antibody Therapy. Cancer Res. 2017; 77(20):5652-5663. DOI: 10.1158/0008-5472.CAN-17-0707. View

Igarashi N, Miyata K, Loo T, Chiba M, Hanyu A, Nishio M . Hepatocyte growth factor derived from senescent cells attenuates cell competition-induced apical elimination of oncogenic cells. Nat Commun. 2022; 13(1):4157. PMC: 9293948. DOI: 10.1038/s41467-022-31642-4. View

10.

Xu Y, Li N, Xiang R, Sun P . Emerging roles of the p38 MAPK and PI3K/AKT/mTOR pathways in oncogene-induced senescence. Trends Biochem Sci. 2014; 39(6):268-76. PMC: 4358807. DOI: 10.1016/j.tibs.2014.04.004. View

11.

Duffy M, Synnott N, OGrady S, Crown J . Targeting p53 for the treatment of cancer. Semin Cancer Biol. 2020; 79:58-67. DOI: 10.1016/j.semcancer.2020.07.005. View

12.

Chen Q, Pu N, Yin H, Zhang J, Zhao G, Lou W . CD73 acts as a prognostic biomarker and promotes progression and immune escape in pancreatic cancer. J Cell Mol Med. 2020; 24(15):8674-8686. PMC: 7412695. DOI: 10.1111/jcmm.15500. View

13.

Schmitt C, Wang B, Demaria M . Senescence and cancer - role and therapeutic opportunities. Nat Rev Clin Oncol. 2022; 19(10):619-636. PMC: 9428886. DOI: 10.1038/s41571-022-00668-4. View

14.

Li Y, Chen X, Zhou Z, Li Q, Westover K, Wang M . Dynamic surveillance of tamoxifen-resistance in ER-positive breast cancer by CAIX-targeted ultrasound imaging. Cancer Med. 2020; 9(7):2414-2426. PMC: 7131861. DOI: 10.1002/cam4.2878. View

15.

Wang Y, Xu H, Han Y, Wu Y, Wang J . Comparative Efficacy of Tyrosine Kinase Inhibitors and Antibody-Drug Conjugates in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A Systematic Review and Network Meta-Analysis. Cancers (Basel). 2022; 14(14). PMC: 9321046. DOI: 10.3390/cancers14143372. View

16.

Robison H, Chini C, Comi T, Ryu S, Ognjanovski E, Perry R . Identification of lipid biomarkers of metastatic potential and gene expression (HER2/p53) in human breast cancer cell cultures using ambient mass spectrometry. Anal Bioanal Chem. 2020; 412(12):2949-2961. DOI: 10.1007/s00216-020-02537-4. View

17.

Thadathil N, Selvarani R, Mohammed S, Nicklas E, Tran A, Kamal M . Senolytic treatment reduces cell senescence and necroptosis in Sod1 knockout mice that is associated with reduced inflammation and hepatocellular carcinoma. Aging Cell. 2022; 21(8):e13676. PMC: 9381894. DOI: 10.1111/acel.13676. View

18.

Ferrando-Diez A, Felip E, Pous A, Bergamino Sirven M, Margeli M . Targeted Therapeutic Options and Future Perspectives for HER2-Positive Breast Cancer. Cancers (Basel). 2022; 14(14). PMC: 9320771. DOI: 10.3390/cancers14143305. View

19.

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

20.

Zhou Q, Ding W, Qian Z, Zhu Q, Sun C, Yu Q . Immunotherapy Strategy Targeting Programmed Cell Death Ligand 1 and CD73 with Macrophage-Derived Mimetic Nanovesicles to Treat Bladder Cancer. Mol Pharm. 2021; 18(11):4015-4028. DOI: 10.1021/acs.molpharmaceut.1c00448. View